Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / PTPN11



This biomarker is also known as:
  • protein-tyrosine phosphatase 1D,
  • protein tyrosine phosphatase, non-receptor type 11,
  • PTP-1D,
  • BPTP3,
  • Protein-tyrosine phosphatase 2C,
  • PTP2C,
  • SHP-2,
  • CFC,
  • Noonan syndrome 1,
  • Protein-tyrosine phosphatase 1D,
  • protein-tyrosine phosphatase 2C,
  • NS1,
  • Shp2,
  • PTP-2C,
  • SHPTP2,
  • tyrosine-protein phosphatase non-receptor type 11,
  • SHP2,
  • EC,
  • SH-PTP2,
  • SH-PTP3,

View in BioMuta


PTPN11 is a member of the protein tyrosine phosphatase (PTP) family. PTP family members are a group of enzymes that catalyze the removal of phosphate groups from tyrosine residues by the hydrolysis of phosphoric acid monoesters. The activity of PTPs opposite that of kinases and phosphorylases and therefore PTPs play an integral role in many signal transduction pathways. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. PTPN11 is widely expressed in most tissues and plays a regulatory role in various cell signaling events that are important for a diversity of cell functions, such as mitogenic activation, metabolic control, transcription regulation, and cell migration.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


No additional breast data available.

Performance Comment

PTPN11 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.